Related Experiment Video
Updated: Jun 27, 2026

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
Published on: April 7, 2023
Evaluation of mifepristone as a once a month contraceptive pill
Mukta Agarwal1, Vinita Das, Anjoo Agarwal
1Department of Obstetrics and Gynecology, CSM Medical University (Upgraded King George's Medical University), Lucknow, UP, India.
Objective:
The purpose of this study was to assess the efficacy and safety of mifepristone as a contraceptive pill.
Study Design:
A prospective case-control study was conducted in a tertiary care center of North India. The study group (n = 86) was given 200-mg mifepristone tablets on the 16th day of the menstrual cycle. The control group (n = 92) received combined oral contraceptive (COC) as per protocol. Subjects were followed for drug compliance, satisfaction, side effects, and failure.
Results:
Acceptability of mifepristone was significantly higher in educated population (P < .001), with fewer side effects (P = .001), good satisfaction (P < .001), and higher compliance rate (P = .05). The oral contraceptive pill group had higher adverse biochemical parameters.
Conclusion:
Mifepristone can be used as a monthly contraceptive pill effectively.
Related Concept Videos
Intrauterine Drug Delivery Systems
Birth Control Methods
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Ovarian Cycle
Modified-Release Drug Delivery Systems: Bioavailability
